Supplement analysis backed by scientific evidence · PT

← All supplements
Limited evidenceJoints & skin

Baikal Skullcap

Chinese skullcap (Scutellaria baicalensis) has one week-long trial for knee osteoarthritis using a proprietary blend, and a documented history of liver injury when its baicalin was sold as the medical food flavocoxid. Interesting flavones, thin human evidence, and a real hepatotoxicity signal.

What the science says

  • Short-term knee joint discomfort (as a blend) Limited evidence

    In a 1-week double-blind trial, 79 adults aged 40-90 with mild-to-moderate knee OA took either 500 mg/day of UP446 (a S. baicalensis + Acacia catechu blend) or 440 mg/day naproxen. The UP446 group had significantly reduced perceived pain (p=0.009), reduced stiffness (p=0.002) and improved range of motion (p=0.04). There was no placebo arm, the trial lasted one week, and the product is a two-herb blend — you cannot attribute the effect to skullcap alone.

  • Liver injury is a documented risk, not a theoretical one Moderate evidence

    Flavocoxid (Limbrel), a prescription medical food combining baicalin from S. baicalensis with catechin, produced a case series of acute liver injury reported by the US Drug-Induced Liver Injury Network, with onset typically within one to three months and resolution after stopping. The FDA later warned about Limbrel and drug-induced liver injury. Supplement-grade skullcap extracts are not the identical product, but the hepatic signal belongs to this plant's flavones.

  • It is not the same plant as calming American skullcap Moderate evidence

    Nearly all consumer sedative and anxiety claims for 'skullcap' derive from Scutellaria lateriflora (American skullcap), a different species with a different chemistry. Baikal skullcap root is dominated by baicalin, baicalein and wogonin and is traditionally used as a heat-clearing anti-inflammatory herb (huang qin), not a nervine. Labels frequently blur the two.

  • Antimicrobial and 'Lyme protocol' use Limited evidence

    S. baicalensis showed activity against stationary-phase Borrelia burgdorferi in a Johns Hopkins in-vitro screen at a 1% extract concentration — a concentration nowhere near achievable in human blood. No clinical trial has tested it in Lyme disease or persistent Lyme symptoms.

Dosage & safety

Studied doseStandardized root extracts are typically sold at 250-1000 mg/day; the knee OA trial used 500 mg/day of the S. baicalensis + A. catechu blend UP446. Traditional decoctions use 3-9 g of dried root daily. No dose has been established for any indication outside these blends.
SafetyThe main concern is hepatotoxicity: baicalin-containing flavocoxid caused a documented case series of acute liver injury and prompted FDA action, and sporadic liver injury reports also exist for skullcap supplements. Stop and get liver enzymes checked if you develop fatigue, dark urine, or jaundice. Baicalin inhibits and induces several drug transporters and CYP enzymes — it has been shown to reduce rosuvastatin exposure — so avoid alongside statins, immunosuppressants, or narrow-therapeutic-index drugs without medical supervision. Avoid in pregnancy and breastfeeding (no safety data). Not banned in sport.

Scientific references

Where to buy

Nutricost, Baikal Skullcap, 500 mg, 120 Capsules

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Joints & skin